KR20240087636A - Kras g12d 억제제 및 이의 용도 - Google Patents
Kras g12d 억제제 및 이의 용도 Download PDFInfo
- Publication number
- KR20240087636A KR20240087636A KR1020247005823A KR20247005823A KR20240087636A KR 20240087636 A KR20240087636 A KR 20240087636A KR 1020247005823 A KR1020247005823 A KR 1020247005823A KR 20247005823 A KR20247005823 A KR 20247005823A KR 20240087636 A KR20240087636 A KR 20240087636A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021108280 | 2021-07-23 | ||
| CNPCT/CN2021/108280 | 2021-07-23 | ||
| CN2021143176 | 2021-12-30 | ||
| CNPCT/CN2021/143176 | 2021-12-30 | ||
| PCT/CN2022/106447 WO2023001141A1 (en) | 2021-07-23 | 2022-07-19 | Kras g12d inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240087636A true KR20240087636A (ko) | 2024-06-19 |
Family
ID=84979988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247005823A Pending KR20240087636A (ko) | 2021-07-23 | 2022-07-19 | Kras g12d 억제제 및 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240376123A1 (https=) |
| EP (1) | EP4373827A4 (https=) |
| JP (1) | JP2024525993A (https=) |
| KR (1) | KR20240087636A (https=) |
| CN (1) | CN117242079A (https=) |
| AU (1) | AU2022314009A1 (https=) |
| CA (1) | CA3226720A1 (https=) |
| WO (1) | WO2023001141A1 (https=) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| CA3211725A1 (en) * | 2021-03-17 | 2022-09-22 | Tao Jiang | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| EP4361157A4 (en) * | 2021-06-21 | 2024-10-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| EP4471037A1 (en) * | 2022-01-30 | 2024-12-04 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinoline compound and use thereof |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CR20240451A (es) * | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| CA3247639A1 (en) | 2022-05-06 | 2023-11-09 | PAQ Therapeutics Inc. | CHIMERAS TARGET KRAS-G12D PROTEOLYSIS |
| CR20240508A (es) * | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024022444A1 (zh) * | 2022-07-27 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| AU2023314335A1 (en) * | 2022-07-29 | 2025-02-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising kras g12d inhibitor |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| WO2024032704A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2024051721A1 (en) * | 2022-09-07 | 2024-03-14 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| AU2023388747A1 (en) * | 2022-12-07 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused cyclic compounds and use thereof |
| EP4640689A1 (en) * | 2022-12-20 | 2025-10-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of kras g12d inhibitor and preparation method therefor |
| WO2024153116A1 (en) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2024234360A1 (en) * | 2023-05-18 | 2024-11-21 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024160225A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics, Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024159471A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024159470A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| EP4695262A1 (en) * | 2023-04-10 | 2026-02-18 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| AU2024252725A1 (en) * | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121100120A (zh) * | 2023-05-07 | 2025-12-09 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2024243186A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL326812A (en) * | 2023-08-25 | 2026-04-01 | Ensem Therapeutics Inc | Tetracyclic substances, preparations containing them and their uses |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| US20250101042A1 (en) * | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025059040A1 (en) * | 2023-09-11 | 2025-03-20 | Newave Pharmaceutical Inc. | Mutant kras modulators and uses thereof |
| CN121941690A (zh) | 2023-10-03 | 2026-04-28 | Paq医疗公司 | Kras蛋白水解靶向嵌合体 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| AR134485A1 (es) * | 2023-11-22 | 2026-01-21 | Genentech Inc | Inhibidores de oxazepina aza-tetracíclica de kras-g12d |
| WO2025111586A1 (en) * | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d |
| WO2025123318A1 (en) * | 2023-12-15 | 2025-06-19 | Shanghai Blueray Biopharma Co., Ltd. | TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| WO2025153038A1 (en) * | 2024-01-17 | 2025-07-24 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| CN119684315A (zh) * | 2024-01-26 | 2025-03-25 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194134A1 (en) * | 2024-03-15 | 2025-09-18 | Genentech, Inc. | Linearly substituted oxazepin-5-one kras-g12d inhibitors |
| WO2025217319A1 (en) * | 2024-04-09 | 2025-10-16 | Kestrel Therapeutics Inc. | Ras inhibitors and methods of use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| US10597405B2 (en) * | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| KR20220012255A (ko) * | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| US12421236B2 (en) * | 2019-06-25 | 2025-09-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor |
| WO2021000885A1 (zh) * | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| CN112300196A (zh) * | 2019-07-30 | 2021-02-02 | 上海凌达生物医药有限公司 | 一类哌啶稠环类化合物、制备方法和用途 |
| JP7756069B6 (ja) * | 2019-08-02 | 2025-11-27 | 上海済▲ユウ▼医薬科技股▲フン▼有限公司 | 四環式化合物、その調製と使用の方法 |
| CN112390818B (zh) * | 2019-08-12 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途 |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021052499A1 (zh) * | 2019-09-20 | 2021-03-25 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| JP7601869B2 (ja) * | 2019-10-30 | 2024-12-17 | ▲勁▼方医▲薬▼科技（上海）有限公司 | 置換された複素環－環系化合物、その調製方法及び医薬への応用 |
| CN113321654B (zh) * | 2020-02-28 | 2022-05-03 | 上海济煜医药科技有限公司 | 作为激酶抑制剂的稠合吡啶酮类化合物 |
| WO2021197499A1 (zh) * | 2020-04-03 | 2021-10-07 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮类化生物 |
| WO2021219072A1 (zh) * | 2020-04-30 | 2021-11-04 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN113929681A (zh) * | 2020-07-14 | 2022-01-14 | 浙江海正药业股份有限公司 | 四环类衍生物及其制备方法和用途 |
| CN113980032B (zh) * | 2020-07-27 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| CN114195788B (zh) * | 2020-09-17 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一类四环化合物及其用途 |
| JP2024500105A (ja) * | 2020-12-15 | 2024-01-04 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | ポリヌクレオチドの改善されたインビトロアセンブリーのための組成物及び方法 |
| WO2022143995A1 (zh) * | 2020-12-31 | 2022-07-07 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
| CA3211725A1 (en) * | 2021-03-17 | 2022-09-22 | Tao Jiang | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN115175354B (zh) * | 2021-04-04 | 2025-07-08 | 华为技术有限公司 | 数据传输方法及装置 |
| EP4361157A4 (en) * | 2021-06-21 | 2024-10-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE |
| AU2022303440A1 (en) * | 2021-07-02 | 2024-02-22 | Shanghai De Novo Pharmatech Co., Ltd. | Kras g12d inhibitor and use thereof |
| CN118265674A (zh) * | 2021-11-16 | 2024-06-28 | 瓦克化学股份公司 | 含低卤化硅的复合颗粒 |
| CR20240451A (es) * | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
-
2022
- 2022-07-19 WO PCT/CN2022/106447 patent/WO2023001141A1/en not_active Ceased
- 2022-07-19 KR KR1020247005823A patent/KR20240087636A/ko active Pending
- 2022-07-19 US US18/290,798 patent/US20240376123A1/en active Pending
- 2022-07-19 CN CN202280009851.5A patent/CN117242079A/zh active Pending
- 2022-07-19 CA CA3226720A patent/CA3226720A1/en active Pending
- 2022-07-19 EP EP22845306.4A patent/EP4373827A4/en active Pending
- 2022-07-19 JP JP2024527720A patent/JP2024525993A/ja active Pending
- 2022-07-19 AU AU2022314009A patent/AU2022314009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022314009A1 (en) | 2024-01-25 |
| WO2023001141A1 (en) | 2023-01-26 |
| CA3226720A1 (en) | 2023-01-26 |
| US20240376123A1 (en) | 2024-11-14 |
| EP4373827A1 (en) | 2024-05-29 |
| EP4373827A4 (en) | 2025-06-04 |
| CN117242079A (zh) | 2023-12-15 |
| JP2024525993A (ja) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240087636A (ko) | Kras g12d 억제제 및 이의 용도 | |
| WO2023284537A1 (en) | Kras g12d inhibitors and uses thereof | |
| WO2024153116A1 (en) | Kras g12d inhibitors and uses thereof | |
| WO2023030517A1 (en) | Kras g12c inhibitors and uses thereof | |
| CN116143805B (zh) | 一类含氮杂环联芳基类化合物、制备方法和用途 | |
| CN117222646A (zh) | Kras g12c抑制剂和其用途 | |
| WO2024153119A1 (en) | Kras g12d inhibitors and uses thereof | |
| AU2021283585A1 (en) | Inhibitors of KRAS G12C protein and uses thereof | |
| CN116332948A (zh) | 一种含氮四环化合物及其制备方法和药用用途 | |
| WO2019158019A1 (zh) | 嘧啶并环化合物及其制备方法和应用 | |
| CN113527299A (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
| WO2025153038A1 (en) | Kras inhibitors and uses thereof | |
| CN106749233A (zh) | 一类磺酰胺衍生物及其应用 | |
| AU2021321905A1 (en) | ATR inhibitors and uses thereof | |
| WO2023036156A1 (zh) | Dna-pk选择性抑制剂及其制备方法和用途 | |
| WO2025157246A1 (zh) | 嘧啶多环类衍生物抑制剂、其制备方法和应用 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| WO2023051464A1 (en) | Pyrazolopyridine compounds as tam inhibitors | |
| TW202218661A (zh) | 作為ｅｇｆｒ抑制劑的三環化合物 | |
| CN114075218A (zh) | Usp7抑制剂 | |
| CN115960109B (zh) | 稠环类shp2磷酸酶抑制剂的制备及其应用 | |
| WO2023155886A1 (en) | Pyrazolopyridine compounds as tam inhibitors | |
| WO2023138621A1 (en) | Atr inhibitors and uses thereof | |
| TW202320767A (zh) | 雜芳基衍生物parp抑制劑及其用途 | |
| AU2013252514B2 (en) | Intermediates and processes for preparing compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |